Tub-tag is a molecular glue that facilitates site-specific conjugation of small chemical molecules to proteins and other biomolecules. Tub-tag is particularly suitable for the development of targeted therapies with an improved side-effect profile. The technology is characterized by extremely high chemical flexibility and has great potential for the development of antibody drug conjugates – promising molecules in the fight against cancer. Tub-tag forms the basis of the BMWi funded start up project Tubulis.
In his second project and with the development of cell-permeable nanobodies, Dominic Schumacher and colleagues were able to observe biomolecules and intracellular processes “live” in living cells. Cell-permeable nanobodies can make a decisive contribution to improving the general understanding of processes inside cells in the future. A key prerequisite for understanding and ultimately treating diseases.

Dominik Schumacher studied business chemistry and chemistry at the University of Düsseldorf and received his master’s degree with highest honors. He conducted his PhD in the lab of Prof. Dr. Christian Hackenberger at the Leibniz-Institut für Molekulare Pharmakologie and the Humboldt Universität zu Berlin focusing on the site-specififc functionalization of proteins (summa cum laude). Since 2017 he is co-leading a junior group at the LMU Munich and the start-up project Tubulis. Dominik Schumacher is first and corresponding author of several publications in renowned journals including Angewandte Chemie, Chemical Science and Nature Chemistry. He received several prizes and was recently awarded as one of Europe’s top innovators under 35.